Luteinizing hormone β polymorphism and risk of familial and sporadic prostate cancer

Prostate

Volumn 56, Issue 1, 2003, Pages 30-36

  Elkins, David A ^a   Yokomizo, Akira ^a   Thibodeau, Stephen N ^a   Schaid, Daniel J ^b   Cunningham, Julie M ^a   Marks, Angela ^a   Christensen, Eric ^a   McDonnell, Shannon K ^b   Slager, Susan ^b   Peterson, Brett J ^b   Jacobsen, Steven J ^b   Cerhan, James R ^b   Blute, Michael L ^b   Tindall, Donald J ^b   Liu, Wanguo ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

Luteinizing hormone; Polymorphism; Prostate cancer

Indexed keywords

ARGININE; ISOLEUCINE; LUTEINIZING HORMONE; LUTEINIZING HORMONE BETA V; TESTOSTERONE; THREONINE; TRYPTOPHAN; UNCLASSIFIED DRUG;

ADENOHYPOPHYSIS; ADULT; AGE; AGED; ARTICLE; BODY MASS; CANCER GRADING; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CAUCASIAN; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FAMILIAL CANCER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HORMONE ACTION; HORMONE RELEASE; HUMAN; HYPOTHESIS; LEYDIG CELL; MAJOR CLINICAL STUDY; MALE; POPULATION; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; FAMILY HEALTH; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUTEINIZING HORMONE, BETA SUBUNIT; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 0038242421     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10220     Document Type: Article

References (31)

1. Ross R, Pike M, Coetzee G, Reichardt J, Yu M, Feigelson H, Stanczyk F, Kolonel L, Henderson B. Androgen metabolism and prostate cancer: Establishing a model of genetic susceptibility. Cancer Res 1998;58:4497-4504.
2. Gann P, Hennekens C, Ma J, Longcope C, Stampfer M. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118-1126.
3. Wolk A, Andersson S-O, Bergstrom R. RE: Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1997;89:820.
4. Shaneyfelt T, Husein R, Bubley G, Mantzoros C. Hormonal predictors of prostate cancer: A meta-analysis. J Clin Oncol 2000;18:847.
5. Bosland M. Chapter 2: The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monographs 2000;27:39-66.
6. Ingles S, Ross R, Yu M, Irvine R, La Pera G, Haile R, Coetzee G. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89:166-170.
7. Febbo P, Kantoff P, Giovannucci E, Brown M, Chang G, Hennekens C, Stampfer M. Debrisoquine hydroxylase (CYP2D6) and prostate cancer. Cancer Epidemiol Biomarkers Prev 1998;7:1075-1078.
8. Murata M, Shiraishi T, Fukutome K, Watanabe M, Nagao M, Kubota Y, Ito H, Kawamura J, Yatani R. Cytochrome P4501A1 and glutathione S-transferase M1 genotypes as risk factors for prostate cancer in Japan. Jpn J Clin Oncol 1998;28:657-660.
9. Rebbeck T, Jaffe J, Walker A, Wein A, Malkowicz S. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998;90:1225-1229.
10. Giovannucci E, Stampfer M, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens C, Kantoff P. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997;94:3320-3323.
11. Murata M, Watanabe M, Yamanaka M, Kubota Y, Ito H, Nagao M, Katoh T, Kamataki T, Kawamura J, Yatani R, Shirashi T. Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1, and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett 2001;165:171-177.
12. Makridakis N, Ross R, Pike M, Crocitto L, Kolonel L, Pearce C, Henderson B, Reichardt J. Association of mis-sense substitution of SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 1999;354:975-978.
13. Lunn R, Bell D, Mohler J, Taylor J. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999;20:1727-1731.
14. Pierce J, Parsons T. Glycoprotein hormones: Structure and function. Annu Rev Biochem 1981;50:465-495.
15. Haavisto A, Pettersson K, Bergendahl M, Virkamaki A, Huhtaniemi I. Occurrence and biological properties of a common genetic variant of luteinizing hormone. J Clin Endocrinol Metab 1995;80:1257-1263.
16. Nilsson C, Pettersson K, Millar R, Coerver K, Matzuk M, Huhtaniemi I. Worldwide frequency of a common genetic variant of luteinizing hormone: An international collaborative research. International Collaborative Research Group. Fertil Steril 1997;67:998-1004.
17. Suganuma N, Furui K, Kikkawa F, Tomoda Y, Furuhashi M. Effects of the mutations (Trp8 → Arg and Ile15 → Thr) in human luteinizing hormone (LH) beta-subunit on LH bioactivity in vitro and in vivo. Endocrinology 1996;137:831-838.
18. Jiang M, Pakarinen P, Zhang FP, El-Hefuawy T, Koskimies P, Pettersson K, Huhtaniemi J. A common polymorphic allele of the human luteinizing hormone beta-subunit gene: Additional mutations and differential function of the promoter sequence. Hum Mol Genet 1999;8:2037-2046.
19. Berry R, Schroeder J, French A, McDonnell S, Peterson B, Cunningham J, Thibodeau S, Schaid D. Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet 2000;67:82-91.
20. Wang L, McDonnell S, Elkins D, Slager S, Christensen E, Marks A, Cunningham J, Peterson B, Jacobsen S, Cerhan J, Blute M, Schaid D, Thibodeau S. Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res 2001;61:6494-6499.
21. Chute C, Panser L, Girman C, Oesterling J, Guess H, Jacobsen S, Lieber M. The prevalence of prostatism: A population-based survey of urinary symptoms. J Urol 1993;150:85-89.
22. Jacobsen S, Guess H, Panser L, Girman C, Chute C, Oesterling J, Lieber M. A population-based study of health care-seeking behavior for treatment of urinary symptoms: The Olmsted County study of urinary symptoms and health status among men. Arch Fam Med 1993;2:729-735.
23. Melton LI. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996;71:266-274.
24. Panser L, Chute C, Guess H, LarsonKeller J, Girman C, Oesterling J, Lieber M, Jacobsen S. The natural history of prostatism: The effects of non-response bias. Int J Epidemiol 1994;23:1198-1205.
25. Oesterling J, Jacobsen S, Chute C, Guess H, Girman C, Panser L, Lieber M. Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges. JAMA 1993;270:860-864.
26. Jacobsen S, Jacobson D, Girman C, Roberts R, Rhodes T, Guess H, Lieber M. Treatment for benign prostatic hyperplasia among community dwelling men: The Olmsted County study of urinary symptoms and health status. J Urol 1999;162:1301-1306.
27. Sasieni P. From genotypes to genes: Doubling the sample size. Biometrics 1997;53:1253-1261.
28. Slager S, Schaid D. Evaluation of candidate genes in case-control studies: A statistical method to account for related subjects. Am J Hum Genet 2001;68:1457-1462.
29. Liang K-Y, Zegler S. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
30. Poole C. Low P-values or narrow confidence intervals: Which are more durable? Epidemiology 2001;12:291-294.
31. Rajkhowa M, Talbot JA, Jones P, Pettersson K, Haavisto A, Huhtaniemi I, Clayton R. Prevalence of an immunological LH beta-subunit variant in a UK population of healthy women and women with polycystic ovary syndrome. Clin Endocrinol 1995;43:297-303.